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DNA polymerase beta bypasses in vitro a single
d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene
Abstract
We have examined the capacity of calf thymus DNA polymerases alpha, beta, delta, and epsilon to
perform in vitro translesion synthesis on a substrate containing a single d(GpG)-cisplatin adduct placed
on codon 13 of the human HRAS gene. We found that DNA synthesis catalyzed by DNA polymerases
alpha, delta, and epsilon was blocked at the base preceding the lesion. Addition of proliferating cell
nuclear antigen to DNA polymerase delta and replication protein A to DNA polymerase alpha did not
restore their capacity to elongate past the adduct. On the other hand, DNA polymerase beta efficiently
bypassed the cisplatin adduct. Furthermore, we observed that DNA polymerase beta was the only
polymerase capable of primer extension of a 3'-OH located opposite the base preceding the lesion.
Likewise, DNA polymerase beta was able to elongate the arrested replication products of the other three
DNA polymerases, thus showing its capacity to successfully compete with polymerases alpha, delta, and
epsilon in the stalled replication complex. Our data suggest (i) a possible mechanism enabling DNA
polymerase beta to bypass a d(GpG)-cisplatin adduct in vitro and (ii) a role for this enzyme in
processing DNA damage in vivo.
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DNA polymerase (3 bypasses in vitro a single d(GpG)-cisplatin
adduct placed on codon 13 of the HRAS gene
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ABSTRACT We have examined the capacity of calf thy-
mus DNA polymerases a, f, 6, and e to perform in vitro
translesion synthesis on a substrate containing a single
d(GpG)-cisplatin adduct placed on codon 13 of the human
HRAS gene. We found that DNA synthesis catalyzed by DNA
polymerases ca, 6, and E was blocked at the base preceding the
lesion. Addition of proliferating cell nuclear antigen to DNA
polymerase i and replication protein A to DNA polymerase a
did not restore their capacity to elongate past the adduct. On
the other hand, DNA polymerase 13 efficiently bypassed the
cisplatin adduct. Furthermore, we observed that DNA poly-
merase ,B was the only polymerase capable ofprimer extension
of a 3'-OH located opposite the base preceding the lesion.
Likewise, DNA polymerase 18 was able to elongate the arrested
replication products ofthe other three DNA polymerases, thus
showing its capacity to successfully compete with polymerases
a, 6, and E in the stalled replication complex. Our data suggest
(i) a possible mechanism enabling DNA polymerase 13 to
bypass a d(GpG)-cisplatin adduct in vitro and (ii) a role for
this enzyme in processing DNA damage in vivo.
Among the possible mechanisms of mutagenesis is error-prone
replication by cellular DNA polymerases past a DNA lesion
followed by fixation of the mutation during subsequent rounds
of replication. In eukaryotic cells, it is still unclear whether the
replicative DNA polymerases a, 8, and E can carry out
translesion synthesis either alone or with the help of accessory
proteins. Alternatively, a separate DNA polymerase may be
required for this process. For example, genetic evidence in the
yeast Saccharomyces cerevisiae indicates that a putative DNA
polymerase, the product of the REV3 gene, may be involved in
error-prone translesion synthesis but not in normal DNA
replication (1). DNA polymerase (3 is one of the five mam-
malian polymerases identified to date and is believed to
function primarily in the repair of damaged DNA (2). How-
ever, DNA polymerase a may also have a role in replicative
synthesis, since the enzyme can substitute forDNA polymerase
I during DNA replication in Escherichia coli (3), and it is
required for the conversion of single-stranded M13 DNA to
double-stranded DNA in Xenopus oocytes and in oocyte
nuclear extracts (4).
cis-Diamminedichloroplatinum(II) (cisplatin) is an antican-
cer agent widely used in the treatment of ovarian, testicular,
head, and neck carcinomas (5). It is believed that this com-
pound exerts its cytotoxic properties by forming stable lesions
on DNA, primarily intrastrand cross-links at the N-7 positions
of adjacent guanine bases [d(GpG)-cisplatin or Pt-d(GpG)]
(6). Replicative bypass of cisplatin adducts has been described
in bacteria (7, 8) and in eukaryotic cells (9). Recent work in our
laboratory has demonstrated that a single-stranded DNA
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement" in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
vector bearing a unique intrastrand bifunctional adduct Pt-
d(GpG) at codon 13 of the human protooncogene HRAS is
replicated in simian COS-7 cells and that such translesion
synthesis may be mutagenic (10).
To our knowledge, the capacities of the major mammalian
replication enzymes to bypass the Pt-d(GpG) lesion have not
been compared. To address this question, we have investigated
the ability of purified calf thymus DNA polymerases a, (3, 8,
and s to catalyze in vitro the bypass synthesis of a single
Pt-d(GpG) adduct placed on codon 13 of the human HRAS
protooncogene, the same sequence used for our previous in
vivo studies (10). Results show that only DNA polymerase 3 is
capable of in vitro translesional synthesis and indicate that its
ability to initiate DNA replication opposite the cisplatin
adduct may be a key step in this process.
MATERIALS AND METHODS
Materials. Calf thymus DNA polymerases a-primase (11), (3
(12), 8, and E (13); proliferating cell nuclear antigen (PCNA;
ref. 14); and replication proteinA (RPA; ref. 15) were purified
as described. One unit of DNA polymerase corresponds to 1
nmol of dNTPs incorporated at 37°C in 60 min. All oligonu-
cleotides were synthesized on Cyclone Plus DNA synthesizer
from MilliGen/Biosearch and purified on 20% polyacrylamide
gel. [y-32P]ATP was from Du Pont/NEN, and T4 polynucle-
otide kinase and DNA ligase were from United States Bio-
chemical. Deoxyribonucleotides were purchased from Phar-
macia. Aci I restriction enzyme was from New England Bio-
labs.
Construction and Purification of the 60-muer and the 60-
mer-Pt Oligonucleotide Substrates. Four oligonucleotides (8-
mer, 14-mer, 38-mer, and the complementary 52-mer) were
annealed by mixing an excess of the 14-mer, 52-mer, and
5'-phosphorylated 38-mer with either the 5'-phosphorylated
8-mer or-the 5'-phosphorylated 8-mer-Pt adduct oligonucle-
otides, which had been purified and characterized as described
(16). After ligation the resulting 60-mer or 60-mer-Pt sub-
strates were purified on a 20% polyacrylamide/7 M urea/30%
formamide denaturing gel. These templates contain the se-
quence of the protooncogeneHRAS from codon 7 to codon 14
(nucleotide 2 to nucleotide 25). For DNA synthesis assays,
these templates were hybridized to a 5'-32P-labeled 17-mer
synthetic primer situated at nucleotides 44-60 (Fig. 1A).
In vitro DNA Replication Assays. In assays for calf thymus
DNA polymerases a, 8, and £, 15-LI reaction mixtures con-
tained 20 mM Hepes (pH 7.8); 3 mM MgCl2; 1 mM dithio-
threitol; and 500 ,uM each of dATP, dCTP, dGTP, and dTTP.
For calf thymus DNA polymerase (3, the reactions (15 ,ul)
contained 25 mM Hepes (pH 8.5); 125 mM NaCl; 5 mM
Abbreviations: PCNA, proliferating cell nuclear antigen; RPA, repli-
cation protein A.
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FIG. 1. In vitro replication of the 60-mer and the 60-mer-Pt
substrates by calf thymus DNA polymerases a, 8, and s. (A) The
60-mer-Pt substrate annealed to a 17-nucleotide-long primer. "p"
indicates the intrastrand bifunctional adduct. (B) One-quarter pico-
mole of 5'-32P-labeled and primed 60-mer or 60-mer-Pt templates
were replicated at 37°C for 2 hr by 5 units of DNA polymerase a, 0.1
unit of DNA polymerase 8, or 0.1 unit of DNA polymerase e. The
positions of the 17-mer (primer), 39-mer (product of synthesis to the
dT base preceding the Pt lesion), and 60-mer (full-size product) are
indicated by arrows. To determine the exact location of the arrest sites,
the intact 60-mer substrate was sequenced by the dideoxy method (17)
and migrated on the gel next to the reaction products. The printed
sequence on the left side corresponds to the template containing the
Pt adduct (k!). Pol indicates DNA polymerases.
MgCl2; and 500 ,uM each of dATP, dCTP, dGTP, and dTTP.
At the end of the reaction, 5 p,l of stopping buffer (90%
formamide/0.1% xylene cyanol/0.1% bromophenol blue/0.1
mM EDTA) was added. Samples were boiled for 5 min and
loaded to a 15% polyacrylamide/7 M urea/30% formamide
gel. The amounts of templates and enzymes as well as the
incubation times are indicated in the figure legends.
RESULTS
Calf Thymus DNA Polymerases a, 8, and E Cannot Bypass
the d(GpG)-Cisplatin Adduct Either Separately or in Com-
bination with Accessory Proteins. To study translesion syn-
thesis by DNA polymerases a, 8, and s, we investigated the
extension of a 5'-phosphorylated 17-mer oligonucleotide
primer on untreated or cisplatin-damaged 60-mer templates.
After these substrates were replicated by the enzymes in the
presence of high concentrations of nucleotide triphosphates to
maximize the opportunity of bypass events (18), the newly
synthesized DNA products were separated by polyacrylamide
gel electrophoresis and visualized by autoradiography (Fig.
1B). When untreated substrate was used, all of the available
primers were extended to full-size (60-mer) products, as
expected for efficient replication by the three DNA poly-
merases. In the case of the cisplatin-modified 60-mer substrate,
all of the reaction products migrated as a 39-mer DNA,
indicating complete arrest of replication opposite to the thy-
midine base (dT) immediately preceding the unique Pt-
d(GpG) adduct. Additional experiments performed either for
longer incubation times or with 10 units of DNA polymerase
a, 6 units of DNA polymerase 8, and 1.3 units of DNA
polymerase - did not show detectable translesion synthesis
(data not shown; also see Fig. 4).
Many accessory proteins participate in eukaryotic DNA
replication. One of the components of this machinery is RPA,
also known as human single-stranded DNA-binding protein or
replication factorA (19). This factor has been shown to reduce
pausing by DNA polymerase a at specific sites in single-
stranded templates (20, 21). We hypothesized that the pres-
ence of RPA might stimulate DNA polymerase a to replicate
across the Pt-d(GpG) bifunctional adduct. Bypass of the
cisplatin adduct was not observed when DNA synthesis was
carried out with 5 units of DNA polymerase a in the presence
of 0.25 pmol of platinated templates and 50, 100, or 200 ng of
RPA protein-concentrations known to alleviate pausing of
DNA polymerase a on M13 single-stranded DNA (21) (data
not shown). Another accessory factor that may modulate
bypass replication at a lesion is PCNA, which enhances the
processivity of DNA polymerase 8 (22) and has been shown to
promote DNA synthesis past cis-syn- and trans-syn-cyclobu-
tane-thymine dimers by calf thymus DNA polymerase 8 in vitro
(23). Polymerase 8 did not bypass.the Pt-d(GpG) adduct in the
presence of comparable amounts of PCNA to those reported
(23) (data not shown).
Taken together, these results show that purified calf thymus
DNA polymerases a, 8, and e stop one base prior to the
Pt-d(GpG) adduct during in vitro replication of the 60-mer
substrate.
Calf Thymus DNA Polymerase f3 Can Bypass the d(GpG)-
Cisplatin Adduct. DNA polymerase ,3 may be necessary in the
final steps of eukaryotic genomic DNA replication for gap-
filling. We therefore decided to study the progression ofDNA
synthesis by this DNA polymerase on the single-stranded
60-mer and 60-mer-Pt substrates. At least 5 units of DNA
polymerase 13 were required to extend all primers to full size
on the unplatinated substrate (data not shown) so that 5 units
or more were used in our experiments. Fig. 2A shows the
replication of 0.12 pmol of treated oligonucleotide by increas-
ing amounts of enzyme. In contrast to what was observed for
DNA polymerases a, 8, and s, DNA synthesis by DNA
polymerase 13 proceeded past the Pt-d(GpG) damage. At the
lowest concentration of enzyme used, two main classes of
products were observed, one arrested by the lesion and the
other corresponding to full-length chains (bypass products).
The 3' termini of the interrupted products were localized
opposite the platinated guanines, in contrast to the position of
the arrest sites detected for DNA polymerases a, 8, and E,
which stopped prior to the adduct (compare lanes a and 13 of
Fig. 2). By increasing the amount of DNA polymerase 1,
efficient translesion synthesis was achieved with a concomitant
disappearance of the stop sites (Fig. 2A). Similar results were
obtained by performing a kinetic study with 0.12 pmol of
template and 15 units of enzyme (Fig. 2B). Here, one can see
that the arrest sites observed at early incubation times were
greatly reduced by increasing the length of the reaction.
Replication of the 60-mer substrates creates anAci I restriction
site, 5'-GCGG-3', which includes the GG sequence bearing the
adduct. Following replication of intact and platinated sub-
strates by DNA polymerase X3, the reaction products were
subjected to digestion by Aci I. Gel analysis of the digestion
products revealed that the full-length products of replication of
the platinated 60-mer (but not of unplatinated control tem-
plate) were resistant to the action of the restriction enzyme
(data not shown). Given the known capacity of the Pt-d(GpG)
adduct to inhibit cleavage by restriction enzymes (24), this
result strongly suggests that the cisplatin lesion is still present
B
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FIG. 2. Replication across the Pt-d(GpG) lesion by calf thymus DNA polymerase ,B. (A) Effect of increasing amounts of DNA polymerase 13
on primer extension of the 60-mer-Pt substrate. Cisplatin-damaged substrate (0.12 pmol) was replicated for 2 hr at 37°C by different amounts of
DNA polymerase (3 as indicated above each lane. In lane a, 0.12 pmol of cisplatin-damaged substrate was replicated for 2 hr at 37°C by 5 units
of DNA polymerase a. Pol indicates DNA polymerases. (B) Kinetics of primer extension on the 60-mer-Pt substrate by DNA polymerase P3. DNA
synthesis was carried out with 15 units of DNA polymerase 1 with 0.12 pmol of cisplatin-damaged substrate at 37°C for the times indicated above
the lanes. Arrows inA andB indicate positions of the primer and reaction products as described in Fig. 1. The bracket on the right side ofB indicates
the position in the template of the two guanines involved in the cisplatin adduct and of the dT preceding them. In lane a, 0.12 pmol of
cisplatin-damaged substrate was replicated for the indicated time by 5 units of DNA polymerase a. Pol indicates DNA polymerases.
in the product synthesized by DNA polymerase (3 on the
platinated substrate.
These data show that purified calf thymus DNA polymerase
(3 can efficiently bypass the Pt-d(GpG) adduct during in vitro
replication of the 60-mer substrate.
Calf Thymus DNA Polymerase 13 Can Initiate Replication
Opposite the d(GpG)-Cisplatin Adduct. One key step in the
Pt-d(GpG) bypass mechanism might be the ability of DNA
polymerase ( to initiate DNA synthesis from the base pre-
ceding the lesion, where elongation by DNA polymerases a, 6,
and s is interrupted. To evaluate this hypothesis, we con-
structed a 60-mer-Pt substrate hybridized to a 39-nucleotide-
long complementary primer, whose 3' dA terminus is posi-
tioned opposite the dT base prior to the lesion (see Fig. 3A).
This substrate, as well as the untreated control template, was
then extended by DNA polymerases a, 8, s, and (3, and the
products were resolved by gel electrophoresis (Fig. 3B). Effi-
cient primer extension was catalyzed by all enzymes on un-
damaged substrate, generating a full-length 60-mer product.
However, DNA synthesis initiation from the position opposite
the cisplatin adduct occurred only when DNA polymerase (3
was used (Fig. 3B, lane f). In experiments performed under
conditions similar to those described for Fig. 3 but without
dNTPs, we observed degradation by the 3' -> 5' exonuclease
activity of the DNA polymerases 8 and s of the 39-mer primer
when hybridized to the platinated substrate (data not shown).
These results indicate that in the replication experiments, the
failure of DNA polymerases 6 and s to extend the primer
hybridized to the platinated substrate is not due to their
inability to bind it.
Taken together, these results suggest a possible mechanism
enabling in vitro bypass of the Pt-d(GpG) adduct by calf
thymus DNA polymerase (3 (see Discussion).
Calf Thymus DNA Polymerase .3 Can Extend Interrupted
DNA Chains Synthesized by DNA Polymerases a, 6, and E.
The data presented so far lead to the question ofwhether DNA
polymerase ,B could replicate through the Pt-d(GpG) adduct
by competing with the DNA polymerases for the primer-
template junction. Therefore, we decided to test whether DNA
polymerase 13 was able to extend the interrupted products of
synthesis by DNA polymerases a, 6, and s. Primer extension
experiments on cisplatin-damaged 60-mer substrate were first
carried out with DNA polymerases a, 8, and - for 2 hr at 37°C
as described in Fig. 1. Only DNA polymerase 13 performed
partial DNA translesion synthesis at this pH, which was
optimal for DNA polymerases a, 8, and s (Fig. 4, lane 13).
Addition of DNA polymerase (3 extended the interrupted
A 39-mer
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FIG. 3. Primer extension from the 3'-OH of dA at the platinated
site by calf thymus DNA polymerases a, (3, 8, and E. (A) 60-mer-Pt
substrate annealed to a 39-nucleotide-long primer. v indicates the
intrastrand bifunctional adduct. (B) Substrate (0.12 pmol) was repli-
cated for 2 hr at 37°C by 5 units ofDNA polymerase a, 0.5 unit ofDNA
polymerase 8, 1.3 units of DNA polymerase s, or 15 units of DNA
polymerase P3. Arrows indicate the positions of the 39-mer primer and
of full-length reaction products. Pol, DNA polymerases.
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FIG. 4. Interrupted chains synthesized by DNA polymerases a, 8,
and E can be extended by DNA polymerase P3. 5'-32P-labeled-primed
60-mer-Pt substrates (0.25 pmol) were extended by different amounts
ofDNA polymerases a, 8, s, and P3 as indicated at the top of the lanes.
Reactions were incubated for 2 hr at 37°C under assay conditions
described in Materials and Methods, except that DNA polymerase ,B
buffer was Hepes (pH 7.8) (lanes a, 8, s, and ,3). After 2 hr of
incubation, 10 units ofDNA polymerase 13 together with 100mM NaCl
(final concentration) were added, and the reaction continued for an
additional 2 hr (lanes a+f3; 8+13; E+P). In lane a+8, 6 units of DNA
polymerase 8 were added to a reaction already incubated 2 hr with
DNA polymerase a; the incubation was then prolonged for an
additional 2 hr. Arrows and bracket are as described in Fig. 2.
chains synthesized byDNA polymerases a, 6, and s to an extent
comparable to DNA polymerase 13 alone (Fig. 4, compare lane
to lane a+ 3, 6+13, and E+13). In control reactions, addition
of fresh DNA polymerases a, 8, or E did not result in
translesion synthesis (see, for example, lane a+6 of Fig. 4).
These results indicate that in vitro DNA polymerase 13 can
replace DNA polymerases a, 8, and s in the stalled replication
complex and extend 3' termini of interrupted products through
the d(GpG)-cisplatin adduct.
DISCUSSION
Replication of damaged DNA represents a major mechanism
for generating mutations. Bypass synthesis of unrepaired le-
sions at mutagenic hot-spot codons of transforming genes may
be an important factor in both the initiation and development
of human cancer. Slow repair has been seen in the p53 gene at
positions frequently mutated in skin cancer (25), and the
replication machinery may pass through the damaged codons
at mutation hot spots with a high frequency of misincorpora-
tion. We have recently reported that a vector containing a
single Pt-d(GpG) adduct placed on codon 13 of the human
HRAS protooncogene was efficiently replicated in monkey
cells and that translesion synthesis could contribute to HRAS-
activating mutations induced by the drug (10). In the present
study, we investigated whether purified eukaryotic DNA poly-
merases could perform in vitro translesion synthesis on the
same platinated sequence used in vivo. For this purpose, we
have constructed a 60-mer oligonucleotide containing part of
the human HRAS sequence and a well-defined Pt-d(GpG)
intrastrand bifunctional adduct at the d(GGT) sequence of
codon 13 (see Fig. 1A).
When we performed primer extension experiments on this
damaged template with purified calf thymus DNA poly-
merases a, 6, and s, we failed to observe any bypass (see Fig.
1B). For all of these enzymes, a strong stop was seen at the
position one base prior to the adduct site, and we detected no
incorporation opposite the damage. The fact that we observed
the same arrest position by the three enzymes suggests that the
size of the products obtained with DNA polymerases 6 and s
is not a consequence of degradation by their proofreading
activities, since such activity is not present in the form of the
DNA polymerase a used here. Inhibition of DNA polymerase
E elongation by a unique Pt-d(GpG) lesion placed on short
synthetic oligomers has been described by Huang et at (26).
Our data show that DNA polymerase E inhibition by the
biadduct can also be obtained on codon 13 of the humanHRAS
protooncogene, a hot spot for mutagenesis in vivo.
We further investigated whether accessory factors involved
at the eukaryotic DNA replication fork could promote bypass
synthesis. RPA, known to reduce DNA polymerase a pausing
(21), did not appear to alleviate DNA polymerase a arrest at
the site of the lesion. PCNA, which functions to increase the
processivity of DNA polymerase 8 and has been shown to
promote its bypass synthesis of UV lesions (23), did not help
DNA polymerase 6 in replicating the Pt-d(GpG) adduct.
In contrast to polymerases a, 6, and £, DNA polymerase 13
is capable of catalyzing the incorporation of nucleotides across
the damaged guanines and of elongating efficiently past the
position of the Pt-d(GpG) adduct to reach full-length 60-mer
products (Fig. 2). This finding may implicate DNA polymerase
13 in the previously observed survival of single-stranded simian
virus 40-based shuttle vectors bearing the same damaged
HRAS sequence (10).
To our knowledge, there has been no previous report that
a purified eukaryotic DNA polymerase can efficiently synthe-
size past a Pt-d(GpG) adduct, one normally considered to be
a strong block to DNA replication. DNA polymerase 1 has
been reported to copy past apurinic sites (27) and to synthesize
in vitro through a cis-syn thymine dimer placed on codon 61 of
HRAS gene (28); however, in contrast to what we observed
with the Pt-d(GpG) adduct, the translesion replication of a
cis-syn dimer does not appear to be specific to DNA poly-
merase 13, since it is also bypassed by DNA polymerase a (28)
and DNA polymerase 6 in the presence of PCNA (23). It is
possible that translesion synthesis observed here may be
influenced by the type of lesion and the sequence context.
Hence, it remains to be determined whether the bypass
observed at codon 13 of the HRAS protooncogene, hot spot for
mutagenesis, could be obtained with the same adduct placed
on a different codon or for another blocking lesion.
What properties of these enzymes might be responsible for
their different capacities to bypass the d(GpG)-cisplatin le-
sion? One feature that distinguishes DNA polymerase 13 is its
small size compared to DNA polymerases a, 6, and E (29).
Recently the crystal structure of polymerase 13 has been solved
(30, 31). It showed structural similarity with two other small
polymerases with which it has no sequence homology, the
Klenow fragment ofE. coli polymerase I [PolI(Kf)] and human
immunodeficiency virus (HIV) reverse transcriptase (RT)
(32). We have observed that PolI(Kf) and RT can also
replicate past the Pt-d(GpG) lesion on the templates used in
this study (data to be published elsewhere). Others have
observed the capacity of PolI(Kf) to bypass in vitro the
Pt-d(GpG) adduct in a different sequence context (33, 34).
Apparently these enzymes not only have structural homology,
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but their capacity to bypass certain DNA damage appears to
be a common functional property that may distinguish proteins
with the Pol ,B/PolI(Kf)/RT structure from larger and more
complex DNA polymerases.
All of the DNA polymerases investigated probably dissoci-
ate from the platinated template. In agreement with this
hypothesis, Huang et at demonstrated that the Pt-d(GpG)
adduct, when placed on the template strand, does not sequester
DNA polymerase - (26). Given its distributive mode of DNA
synthesis (29), DNA polymerase 3 likely dissociates and reas-
sociates frequently with the substrate. The particular ability of
polymerase ,B to catalyze in vitro extension from the position
prior to the platinated guanines appears to reflect its capacity
to reinitiate DNA replication at the site opposite the adduct,
while DNA polymerases a, 8, and s appear to be unable to
reinitiate DNA synthesis at this position (see Fig. 3). Further-
more, experiments shown in Fig. 4 indicate that DNA poly-
merase /3 was able to compete with DNA polymerases a, 6, and
e at the stalled replication complex. We propose that the
simple subunit composition of polymerase , (30, 31) may favor
reassociation of the enzyme to a primer-template junction
with damaged bases. Taken together, our results suggest a
possible role of DNA polymerase 13 in the bypass of d(GpG)-
cisplatin DNA lesions in vivo. In this respect, it is interesting
to note that induction of DNA polymerase (3 mRNA by
DNA-damaging agents has been described in CHO cells (35).
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